Retina Regeneration Therapy effective in ME

Article

Ellex's 2RT, a Retina Regeneration Therapy, is safe and effective in the treatment of macular oedema (ME) secondary to diabetic retinopathy (DR), according to study results presented at this year's American Academy of Ophthalmology meeting.

Ellex 2RT, a Retina Regeneration Therapy, is safe and effective in the treatment of macular oedema (ME) secondary to diabetic retinopathy (DR), according to study results presented at this year's American Academy of Ophthalmology meeting. Ellex 2RT uses a green YAG laser to target the retinal pigment epithelium with 532 nm light energy, delivered in three-nanosecond pulses.

Professor John Marshall, PhD, FRCPath, FRCOphth (Hons), of St. Thomas' Hospital, London, UK, and colleagues treated the newly-diagnosed diabetic maculopathy of 23 patients (eyes, n=38) with Ellex 2RT to modify the macular grid pattern. Of the patients enrolled in the trial, 17 eyes (n=28) completed the six-month follow-up period.

At the six-month follow-up visit, central macular thickness had decreased by ≥5% from baseline in 46% of patients; it remained stable in 39% of patients and increased by ≥5% in the remaining 15%. Hard exudates were decreased in >50% of treated eyes. An improvement of ≥2 lines of LogMar visual acuity was observed in 43% of eyes; of 1–2 lines, in 28%. Visual acuity remained stable in 15% of eyes and decreased in 14%.

The device's manufacturers, Ellex, now plans to investigate the role of Ellex 2RT as a therapeutic in other indications, including age-related macular degeneration and central serous retinopathy.

Newsletter

Join ophthalmologists across Europe—sign up for exclusive updates and innovations in surgical techniques and clinical care.

Recent Videos
Christine Curcio, PhD, of the University of Alabama at Birmingham Heersink School of Medicine, shares histology update and revised nomenclature for OCT with Sheryl Stevenson of the Eye Care Network and Ophthalmology Times
SriniVas R. Sadda, MD, FARVO, shares key points from his retina presentation at the International SPECTRALIS Symposium
Robert Sergott, MD, describes fluorescence lifetime imaging ophthalmoscopy (FLIO) and the International SPECTRALIS Symposium – And Beyond (ISS) in Heidelberg, Germany.
Rayaz Malik, MBChB, PhD, a professor of medicine at Weill Cornell Medicine - Qatar, spoke with Ophthalmology Times Europe about his presentation. It's titled "An eye on neurodegenerative diseases: Challenging the dogma" at the International SPECTRALIS Sympsoium. In conversation with Hattie Hayes, Ophthalmology Times Europe
Anat Loewenstein, MD, describes her presentation on remote imaging for age-related macular degeneration and geographic atrophy at the International SPECTRALIS Symposium, in conversation with Hattie Hayes of Ophthalmology Times Europe
Tyson Brunstetter, OD, PhD, a US Navy Aerospace Optometrist at the NASA Johnson Space Center in Houston, Texas, shares key takeaways from his keynote at the International SPECTRALIS Symposium (ISS)
Rayaz Malik, MBChB, PhD, shares his presentation, titled An eye on neurodegenerative diseases: Challenging the dogma, at this year's International SPECTRALIS Symposium
At the Retina World Congress, Siegfried Priglinger, MD, speaks about ensuring the best outcomes for preschool-aged patients
At the 2025 ASCRS meeting, Robert Ang, MD said small aperture IOLs can benefit all patients, especially those with complex corneas or who have undergone previous corneal refractive surgery
Viha Vig, MBChB graduate student at the University of Auckland, New Zealand, discusses her poster presentation on the relationship between mitochondiral disease, Alzheimer disease, and other types of dementia.
© 2025 MJH Life Sciences

All rights reserved.